Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India)

Abstract

BackgroundDermatophytosis management has become an important public health issue, with a large void in research in the area of disease pathophysiology and management. Current treatment recommendations appear to lose their relevance in the current clinical scenario. The objective of the current consensus was to provide an experience-driven approach regarding the diagnosis and management of tinea corporis, cruris and pedis.MethodsEleven experts in the field of clinical dermatology and mycology participated in the modified Delphi process consisting of two workshops and five rounds of questionnaires, elaborating definitions, diagnosis and management. Panel members were asked to mark “agree” or “disagree” beside each statement, and provide comments. More than 75% of concordance in response was set to reach the consensus.ResultKOH mount microscopy was recommended as a point of care testing. Fungal culture was recommended in chronic, recurrent, relapse, recalcitrant and multisite tinea cases. Topical monotherapy was recommended for naïve tinea cruris and corporis (localised) cases, while a combination of systemic and topical antifungals was recommended for naïve and recalcitrant tinea pedis, extensive lesions of corporis and recalcitrant cases of cruris and corporis. Because of the anti-inflammatory, antibacterial and broad spectrum activity, topical azoles should be preferred. Terbinafine and itraconazole should be the preferred systemic drugs. Minimum duration of treatment should be 2–4 weeks in naïve cases and > 4 weeks in recalcitrant cases. Topical corticosteroid use in the clinical practice of tinea management was strongly discouraged.ConclusionThis consensus guideline will help to standardise care, provide guidance on the management, and assist in clinical decision-making for healthcare professionals.

The current Indian epidemic of superficial dermatophytosis due toTrichophyton mentagrophytes—A molecular study

“…Nationwide epidemiological studies, research for creating evidence and finally Indian treatment guidelines, are the need of the hour. Recently, “Indian National Guidelines” has been published by a group of workers with the help of an unrestricted grant from an industry . All of the above make this interesting and unusual Indian epidemic of dermatophytosis associated with the widespread abuse of topical steroids and FDCs containing TCS a unique disease entity that urgently needs to be addressed not only at a medical level but also at the level of policymakers and regulatory authorities.…”

Major challenges and perspectives in the diagnostics and treatment of dermatophyte infections

“…Moreover, antifungal substances used against dermatophytes must, above all, easily penetrate into keratinized surface structures and persist therein long enough to achieve a therapeutic effect (Rajagopalan et al 2018;Monod et al 2019). Unfortunately, the current arsenal of therapeutic agents is characterized by poor ability to penetrate such structures, which can indirectly result in drug tolerance and drug resistance in dermatophytes, as a result of their exposure to sub-lethal drug concentrations.…”

Impact on quality of life in patients with dermatophytosis

“…The distribution and pattern of dermatophytosis, however, may vary with geographical location, socio‐economic and cultural factors . The reported prevalence of dermatophytosis in India ranges from 36.6 to 78.4% . Clinico‐epidemiological and clinico‐mycological studies on dermatophytic infections in the recent past from different regions of India have reported an increasing trend in the prevalence along with a change in the clinical spectrum and isolation of uncommon species .…”